Dermata Therapeutics, Inc. (DRMAW) — This stock currently has no analyst coverage. No price targets, ratings, or earnings estimates are available. This is common for preferred shares, warrants, OTC-traded securities, and smaller companies that are not followed by Wall Street analysts.
Los analistas estiman Beneficio por acción (EPS) de $-147.80 y ingresos de $0.00B para el próximo año fiscal.
Historial de Beneficio por acción (EPS): 2024: real $-8,032.22 vs est $-147.80 (no alcanzó -5334.5%). 2025: real $-8.16 vs est $-8.00 (no alcanzó -2%). Precisión del analista: 50%.
